UBS Group’s Curanex Pharmaceuticals CURX Stock Holding History

UBS Group’s Portfolio CURX Stock Details CURX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.08K	Sell	7,995 -4,996	-38%	-$1.88K	﹤0.01%	8992
2025 Q4	$4.3K	Sell	12,991 -51,525	-80%	-$28.3K	﹤0.01%	8857
2025 Q3	$46.5K	Buy	+64,516	New	+$292K	﹤0.01%	7619

Other funds holding CURX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

UBS Group's CURX Position: Q1 2026 in Review

UBS Group reduced its Curanex Pharmaceuticals (CURX) stake by 38% in Q1 2026, selling an estimated $1.88K and leaving 7,995 shares worth $4.08K. The position accounts for ﹤0.01% of the portfolio, ranked #8992.

UBS Group first reported a position in CURX in Q3 2025 and has held it in 3 quarters since. The position peaked at $46.5K in Q3 2025. 8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

UBS Group held 7,995 shares of Curanex Pharmaceuticals worth $4.08K as of Q1 2026.
UBS Group sold 4,996 Curanex Pharmaceuticals shares in Q1 2026, an estimated $1.88K.
Curanex Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8992 holding.
UBS Group first reported a position in Curanex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
UBS Group's Curanex Pharmaceuticals position peaked at $46.5K in Q3 2025.
8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.